Comparison of Radiation Dose Estimation for Myeloablative Radioimmunotherapy for Relapsed or Recurrent Mantle Cell Lymphoma Using131I Tositumomab to That of Other Types of Non-Hodgkin's Lymphoma-Reference-Cited by-同舟云学术

Comparison of Radiation Dose Estimation for Myeloablative Radioimmunotherapy for Relapsed or Recurrent Mantle Cell Lymphoma Using131I Tositumomab to That of Other Types of Non-Hodgkin's Lymphoma

Published:2004-12 Issue:6 Volume:19 Page:738-745
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Rajendran Joseph¹,Gopal Ajay²³,Durack Lawrence⁴,Fisher Darrell⁴,Press Oliver²³,Eary Janet¹

Affiliation:

1. Department of Radiology and University of Washington, Seattle, WA

2. Department of Medical Oncology, University of Washington, Seattle, WA

3. Fred Hutchinson Cancer Research Center, Seattle, WA

4. Pacific Northwest National Laboratories, Richland, WA

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.2004.19.738

Reference37 articles.

1. Mantle Cell Lymphoma: A Clinicopathologic Study of 80 Cases

2. Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20-year period

3. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group.

4. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study

5. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction;Journal of Visualized Experiments;2019-01-29

2. 131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin’s lymphoma;Nuclear Medicine Communications;2012-12

3. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways;Blood;2007-06-15

4. Biological Therapy of Non-Hodgkin's Lymphomas;The Lymphomas;2006

5. Current Awareness in Hematological Oncology;Hematological Oncology;2005-09-26